AustralianSuper’s United Therapeutics UTHR Stock Holding History

AustralianSuper’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.5M	Buy	89,590 +75,899	+554%	+$42.7M	0.21%	101
2026 Q1	$8.12M	Sell	13,691 -2,048	-13%	-$1.02M	0.04%	186
2025 Q4	$7.67M	Sell	15,739 -82,261	-84%	-$38.3M	0.04%	176
2025 Q3	$41.1M	Sell	98,000 -189,845	-66%	-$63.8M	0.19%	99
2025 Q2	$82.7M	Buy	287,845 +5,106	+2%	+$1.53M	0.42%	59
2025 Q1	$87.2M	Buy	282,739 +92,959	+49%	+$31.9M	0.49%	65
2024 Q4	$67M	Buy	189,780 +161,751	+577%	+$59.5M	0.32%	85
2024 Q3	$10M	Buy	28,029 +2,998	+12%	+$1.01M	0.05%	106
2024 Q2	$7.97M	Buy	+25,031	New	+$6.62M	0.05%	109
2019 Q3	–	Sell	-90,421	Closed	-$7.06M	–	170
2019 Q2	$7.06M	Sell	90,421 -8,852	-9%	-$828K	0.07%	120
2019 Q1	$11.7M	Buy	99,273 +82,616	+496%	+$9.63M	0.12%	96
2018 Q4	$1.81M	Buy	+16,657	New	+$1.93M	0.03%	102

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

AustralianSuper's UTHR Position: Q2 2026 in Review

AustralianSuper increased its United Therapeutics (UTHR) stake by 554% in Q2 2026, buying an estimated $42.7M and bringing the position to 89,590 shares worth $48.5M. The position accounts for 0.21% of the portfolio, ranked #101.

AustralianSuper first reported a position in UTHR in Q4 2018 and has held it in 12 quarters since. The position peaked at $87.2M in Q1 2025. 879 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

AustralianSuper held 89,590 shares of United Therapeutics worth $48.5M as of Q2 2026.
AustralianSuper bought 75,899 United Therapeutics shares in Q2 2026, an estimated $42.7M.
United Therapeutics made up 0.21% of AustralianSuper's portfolio in Q2 2026, its #101 holding.
AustralianSuper first reported a position in United Therapeutics in Q4 2018 and has held it in 12 quarters since.
AustralianSuper's United Therapeutics position peaked at $87.2M in Q1 2025.
879 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on AustralianSuper's 13F filing for Q2 2026, filed 12 Aug 2026.